Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis

Bellinato, Francesco; Gisondi, Paolo; Mason, Elena Jane; Ricci, Paolo; Maurelli, Martina; Girolomoni, Giampiero

doi:10.1007/s13555-022-00732-y

Cited by 11 publications

(5 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…[ 45 ] In the pathogenesis of psoriasis, IL‐17 and IL‐22 secreted by cutaneous γδT cells induce inflammatory cell recruitment in the skin and abnormal keratinocyte proliferation. [ 46 , 47 , 48 , 49 ] In this study, we elucidated the mechanism that catecholamines directly affect another type 17 immune response of γδT cells, but not Th17 cells. Restraint stress and cutaneous sympathectomy increased and decreased the NE levels in the IMQ‐treated skin, respectively.…”

Section: Discussionmentioning

confidence: 99%

Cutaneous Calcium/Calmodulin‐Dependent Protein Kinase II‐γ–Positive Sympathetic Nerves Secreting Norepinephrine Dictate Psoriasis

Yu,

Chen,

et al. 2024

Advanced Science

View full text Add to dashboard Cite

Cutaneous sympathetic nerve is a crucial part of neuropsychiatric factors contributing to skin immune response, but its role in the psoriasis pathogenesis remains unclear. It is found that cutaneous calcium/calmodulin‐dependent protein kinase II‐γ (CAMK2γ), expressed mainly in sympathetic nerves, is activated by stress and imiquimod in mouse skin. Camk2g‐deficient mice exhibits attenuated imiquimod‐induced psoriasis‐like manifestations and skin inflammation. CaMK2γ regulates dermal γδT‐cell interleukin‐17 production in imiquimod‐treated mice, dependent on norepinephrine production following cutaneous sympathetic nerve activation. Adrenoceptor β1, the primary skin norepinephrine receptor, colocalises with γδT cells. CaMK2γ aggravates psoriasiform inflammation via sympathetic nerve–norepinephrine–γδT cell–adrenoceptor β1–nuclear factor‐κB and –p38 axis activation. Application of alcaftadine, a small‐molecule CaMK2γ inhibitor, relieves imiquimod‐induced psoriasis‐like manifestations in mice. This study reveals the mechanisms of sympathetic‐nervous‐system regulation of γδT‐cell interleukin‐17 secretion, and provides insight into neuropsychiatric factors dictating psoriasis pathogenesis and new potential targets for clinical psoriasis treatment.

show abstract

Section: Discussionmentioning

confidence: 99%

Cutaneous Calcium/Calmodulin‐Dependent Protein Kinase II‐γ–Positive Sympathetic Nerves Secreting Norepinephrine Dictate Psoriasis

Yu,

Chen,

et al. 2024

Advanced Science

View full text Add to dashboard Cite

show abstract

“…12 Environmental, microbial and chemical triggers, in addition, to enhancing cutaneous autonomic activity, also lead to activation of various TLRs, PARs and TRP channels (expressed on CSANs) initiating neurogenic inflammatory cascade in psoriasis. [102][103][104][105] An interaction between nociceptive CSANs, CICs and KCs (Figure 3A) lies at the cornerstone of development and progression of psoriasis as is evident by a higher density of CSANs in psoriatic plaques. [106][107][108] TRPV1+/Na v 1.8+CSANs communicate with dDCs due to their proximity.…”

Section: Cine Loop In Psoriasismentioning

confidence: 99%

“…Many pro‐inflammatory cytokines and chronic stress factors cause dysregulation of the usual stress‐immune response 12 . Environmental, microbial and chemical triggers, in addition, to enhancing cutaneous autonomic activity, also lead to activation of various TLRs, PARs and TRP channels (expressed on CSANs) initiating neurogenic inflammatory cascade in psoriasis 102–105 …”

Section: Cine Loop In Health and Diseasementioning

confidence: 99%

Cutaneous‐immuno‐neuro‐endocrine (CINE) system: A complex enterprise transforming skin into a super organ

Shastri,

Sharma,

Sharma

et al. 2024

Experimental Dermatology

View full text Add to dashboard Cite

Skin is now emerging as a complex realm of three chief systems viz. immune system, nervous system, and endocrine system. The cells involved in their intricate crosstalk, namely native skin cells, intra‐cutaneous immune cells and cutaneous sensory neurons have diverse origin and distinct functions. However, recent studies have explored their role beyond their pre‐defined functional boundaries, such that the cells shun their traditional functions and adopt unconventional roles. For example, the native skin cells, apart from providing for basic structural framework of skin, also perform special immune functions and participate in extensive neuro‐endocrine circuitry, which were traditionally designated as functions of cutaneous resident immune cells and sensory neurons respectively. At the cellular level, this unique collaboration is brought out by special molecules called neuromediators including neurotransmitters, neuropeptides, neurotrophins, neurohormones and cytokines/chemokines. While this intricate crosstalk is essential for maintaining cutaneous homeostasis, its disruption is seen in various cutaneous diseases. Recent study models have led to a paradigm shift in our understanding of pathophysiology of many such disorders. In this review, we have described in detail the interaction of immune cells with neurons and native skin cells, role of neuromediators, the endocrine aspect in skin and current understanding of cutaneous neuro‐immuno‐endocrine loop in one of the commonest skin diseases, psoriasis. An accurate knowledge of this unique crosstalk can prove crucial in understanding the pathophysiology of different skin diseases and allow for generation of targeted therapeutic modalities.

show abstract

“…Thus, the evidence for the similarity of tolerability and efficacy of the biosimilar to the originator biologic is further strengthened through accumulating real-world evidence [ 10 , 33 – 41 ]. Indeed, a substantial body of real-world evidence already exists in multiple indications, including psoriasis, providing confidence in biosimilar use in clinical practice [ 37 – 40 ]. Loft et al examined the real-world effectiveness of adalimumab biosimilars (SB5 and GP2017) by assessing the 1-year drug retention in 348 patients switching to adalimumab biosimilars compared with 378 patients treated with adalimumab originator.…”

Section: Unmet Medical Needs and Potential Role Of Biosimilarsmentioning

confidence: 99%

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

Girolomoni,

Savage,

Gisondi

et al. 2023

Dermatol Ther (Heidelb)

Self Cite

View full text Add to dashboard Cite

Psoriasis is a chronic, immune-mediated inflammatory disease with a worldwide prevalence ranging between 0.51 and 11.43%. It results in a large clinical and social burden, with patients frequently suffering from reduced quality of life, psychologic distress and debilitating comorbidities. Biologic agents are used to establish and maintain disease control in patients with moderate-to-severe psoriasis and are essential to improving quality of life. However, a substantial proportion of patients have limited access to therapy due to economics, health policies and clinical considerations, which creates clinical unmet needs that disadvantage both patients and healthcare professionals. Biosimilars are a cost-effective alternative to off-patent biologic therapies, and there is mounting evidence to suggest they offer a valuable pharmacoeconomic strategy to lower healthcare costs in patients with psoriasis. Furthermore, the introduction of biosimilars can increase the number of patients able to receive biologics, allowing these patients to be treated earlier in the disease course, potentially modifying the course of their disease and reducing the risk of comorbidities. In time, the emergence of additional data, particularly those related to long-term safety, efficacy in extrapolated indications and the effects of switching, should reassure physicians and help overcome the final hurdles for a wider implementation of biosimilars. This review aims to provide an overview of current treatment approaches for patients with moderate-to-severe psoriasis in the biosimilars era and explores both the current challenges and potential opportunities to improve access to high-quality, effective treatments.

show abstract

Real-Life Effectiveness of Adalimumab Biosimilars in Patients with Chronic Plaque Psoriasis

Cited by 11 publications

References 27 publications

Cutaneous Calcium/Calmodulin‐Dependent Protein Kinase II‐γ–Positive Sympathetic Nerves Secreting Norepinephrine Dictate Psoriasis

Cutaneous Calcium/Calmodulin‐Dependent Protein Kinase II‐γ–Positive Sympathetic Nerves Secreting Norepinephrine Dictate Psoriasis

Cutaneous‐immuno‐neuro‐endocrine (CINE) system: A complex enterprise transforming skin into a super organ

Increasing Access to Effective Systemic Treatments in Patients with Moderate-to-Severe Psoriasis: Narrative Review

Contact Info

Product

Resources

About